{"nct_id":"NCT05328102","title":"Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)","status":"TERMINATED","status_verified_date":"2024-04","start_date":"2022-04-15","start_date_type":"ACTUAL","primary_completion_date":"2023-02-21","primary_completion_date_type":"ACTUAL","completion_date":"2023-02-21","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["XNCR"]}